Compare EVGN & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVGN | CLDI |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9M | 9.9M |
| IPO Year | N/A | N/A |
| Metric | EVGN | CLDI |
|---|---|---|
| Price | $1.07 | $1.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.50 | N/A |
| AVG Volume (30 Days) | 47.3K | ★ 91.9K |
| Earning Date | 11-20-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,016,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.35 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.19 | N/A |
| 52 Week Low | $0.95 | $1.10 |
| 52 Week High | $2.42 | $24.24 |
| Indicator | EVGN | CLDI |
|---|---|---|
| Relative Strength Index (RSI) | 44.04 | 52.02 |
| Support Level | $1.03 | $1.41 |
| Resistance Level | $1.19 | $1.55 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 34.62 | 88.57 |
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.